美银证券：中国CXO行业受惠生物科技融资强劲上调药明康德(02359)等目标价

智通财经08-13

智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调行业终端增长率假设，由1%提升至3%，并调升多家CXO企业的目标价。美银指出，根据Pharmcube数据，2026年上半年中国一级市场医疗保健融资共814宗，同比增13.8%，融资总额达726亿元人民币，同比增...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2659182702?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-13 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659182702","market":"sh","top_or_hot":-1,"title":"美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德(02359)等目标价","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调行业终端增长率假设，由1%提升至3%，并调升多家CXO企业的目标价。美银指出，根据Pharmcube数据，2026年上半年中国一级市场医疗保健融资共814宗，同比增13.8%，融资总额达726亿元人民币，同比增...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1479310.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德(02359)等目标价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德(02359)等目标价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-13 10:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1479310.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调行业终端增长率假设，由1%提升至3%，并调升多家CXO企业的目标价。美银指出，根据Pharmcube数据，2026年上半年中国一级市场医疗保健融资共814宗，同比增13.8%，融资总额达726亿元人民币，同比增...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1479310.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FHLC","symbol_name":"Fidelity MSCI Health Care Index","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1479310.html","article_id":"2659182702","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659182702","pubTimestamp":1786587659,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","603259":"药明康德","FHLC":"Fidelity MSCI Health Care Index","02359":"药明康德","PSIL":"AdvisorShares Psychedelics ETF","IDNA":"iShares Genomics Immunology and Healthcare ETF","APXH":"APEX HealthCare ETF","SURI":"SIMPLIFY PROPEL OPPORTUNITIES ETF","PSCH":"Invesco S&P SmallCap Health Care ETF","CXO":"康休","MEDI":"HARBOR HEALTH CARE ETF","SMCO":"HILTON SMALL-MIDCAP OPPORTUNITY ETF","BBC":"Virtus LifeSci Biotech Clinical Trials ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","WX":"Corgi All World 2x Daily ETF","XBIX":"Corgi U.S. Biotech 2x Daily ETF","BMED":"iShares Health Innovation Active ETF","IBRN":"iShares Neuroscience and Healthcare ETF"},"translate_title":"Bank of America Securities: China's CXO industry benefits from strong biotech financing and raises target prices such as WuXi AppTec (02359)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1.5,"603259":1.5,"02359":1.5,"IBRN":1.5,"LFSC":1.5,"PSIL":1.5,"SURI":1.5,"WX":1.5,"PSCH":1.5,"CXO":1.5,"XBIX":1.5,"IDNA":1.5,"APXH":1.5,"FHLC":1.5,"SMCO":1.5,"MEDI":1.5,"BBC":1.5,"BMED":1.5},"content_text":"智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调行业终端增长率假设，由1%提升至3%，并调升多家CXO企业的目标价。美银指出，根据Pharmcube数据，2026年上半年中国一级市场医疗保健融资共814宗，同比增13.8%，融资总额达726亿元人民币，同比增41.7%;其中创新药融资418亿元人民币，同比增79.1%。全球创新药融资方面，上半年融资事件505宗，同比增6.1%，融资总额268亿美元，同比增58.5%。对外授权交易方面，中国相关交易达210宗，首付款总额54亿美元，交易总值1,051亿美元，同比增73%。该行上调药明康德(02359)H股目标价由204.3港元至242港元，药明康德A股(603259.SH)目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。康龙化成(03759)H股目标价由27港元上调至32.3港元，康龙化成(300759.SZ)A股目标价由23.8元人民币上调至28.4元人民币，H股维持“买入”、A股维持“跑输大市”，因A股估值相对较高。药明生物(02269)目标价由39.5港元上调至47.3港元，维持“中性”，平衡其强大执行力与相对同业较不吸引的估值。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659182702","isCrawlerRequest":true}

美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德(02359)等目标价

精彩评论

美银证券：中国CXO行业受惠生物科技融资强劲上调药明康德(02359)等目标价